Research ExplorerPublicationsSecond-line and third-line therapy for autoimmune hepatitis:...

Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group

Standard

Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. / Lohse, Ansgar W; Sebode, Marcial; Jørgensen, Marianne H; Ytting, Henriette; Karlsen, Tom H; Kelly, Deirdre; Manns, Michael P; Vesterhus, Mette; European Reference Network on Hepatological Diseases (ERN RARE-LIVER).

In: J HEPATOL, Vol. 73, No. 6, 12.2020, p. 1496-1506.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Lohse, AW, Sebode, M, Jørgensen, MH, Ytting, H, Karlsen, TH, Kelly, D, Manns, MP, Vesterhus, M & European Reference Network on Hepatological Diseases (ERN RARE-LIVER) 2020, 'Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group', J HEPATOL, vol. 73, no. 6, pp. 1496-1506. https://doi.org/10.1016/j.jhep.2020.07.023

APA

Lohse, A. W., Sebode, M., Jørgensen, M. H., Ytting, H., Karlsen, T. H., Kelly, D., Manns, M. P., Vesterhus, M., & European Reference Network on Hepatological Diseases (ERN RARE-LIVER) (2020). Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. J HEPATOL, 73(6), 1496-1506. https://doi.org/10.1016/j.jhep.2020.07.023

Vancouver

Lohse AW, Sebode M, Jørgensen MH, Ytting H, Karlsen TH, Kelly D et al. Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. J HEPATOL. 2020 Dec;73(6):1496-1506. https://doi.org/10.1016/j.jhep.2020.07.023

Bibtex

@article{64d5b6fe06b345828c40124f4e33b4e3,
title = "Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group",
abstract = "Most patients with autoimmune hepatitis respond well to standard immunosuppressive therapy with steroids and azathioprine, and while untreated disease is usually fatal, patients who respond well to therapy have an excellent prognosis. However, insufficient response to standard therapy or intolerable side effects requiring dose adaptions or treatment changes occur in 10-20% of patients. While there is fairly good agreement on second-line treatment options, there is very wide variation in the indication and use of possible third-line therapies. Herein, the European Reference Network on Hepatological Diseases (ERN RARE-LIVER) and the International Autoimmune Hepatitis Group (IAIHG) outline a treatment algorithm for both children and adults that should help to standardise treatment approaches, in order to improve patient care and to enable the comparison of treatment results between scientific publications.",
author = "Lohse, {Ansgar W} and Marcial Sebode and J{\o}rgensen, {Marianne H} and Henriette Ytting and Karlsen, {Tom H} and Deirdre Kelly and Manns, {Michael P} and Mette Vesterhus and {European Reference Network on Hepatological Diseases (ERN RARE-LIVER)}",
note = "Copyright {\textcopyright} 2020. Published by Elsevier B.V.",
year = "2020",
month = dec,
doi = "10.1016/j.jhep.2020.07.023",
language = "English",
volume = "73",
pages = "1496--1506",
journal = "J HEPATOL",
issn = "0168-8278",
publisher = "Elsevier",
number = "6",

}

RIS

TY - JOUR

T1 - Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group

AU - Lohse, Ansgar W

AU - Sebode, Marcial

AU - Jørgensen, Marianne H

AU - Ytting, Henriette

AU - Karlsen, Tom H

AU - Kelly, Deirdre

AU - Manns, Michael P

AU - Vesterhus, Mette

AU - European Reference Network on Hepatological Diseases (ERN RARE-LIVER)

N1 - Copyright © 2020. Published by Elsevier B.V.

PY - 2020/12

Y1 - 2020/12

N2 - Most patients with autoimmune hepatitis respond well to standard immunosuppressive therapy with steroids and azathioprine, and while untreated disease is usually fatal, patients who respond well to therapy have an excellent prognosis. However, insufficient response to standard therapy or intolerable side effects requiring dose adaptions or treatment changes occur in 10-20% of patients. While there is fairly good agreement on second-line treatment options, there is very wide variation in the indication and use of possible third-line therapies. Herein, the European Reference Network on Hepatological Diseases (ERN RARE-LIVER) and the International Autoimmune Hepatitis Group (IAIHG) outline a treatment algorithm for both children and adults that should help to standardise treatment approaches, in order to improve patient care and to enable the comparison of treatment results between scientific publications.

AB - Most patients with autoimmune hepatitis respond well to standard immunosuppressive therapy with steroids and azathioprine, and while untreated disease is usually fatal, patients who respond well to therapy have an excellent prognosis. However, insufficient response to standard therapy or intolerable side effects requiring dose adaptions or treatment changes occur in 10-20% of patients. While there is fairly good agreement on second-line treatment options, there is very wide variation in the indication and use of possible third-line therapies. Herein, the European Reference Network on Hepatological Diseases (ERN RARE-LIVER) and the International Autoimmune Hepatitis Group (IAIHG) outline a treatment algorithm for both children and adults that should help to standardise treatment approaches, in order to improve patient care and to enable the comparison of treatment results between scientific publications.

U2 - 10.1016/j.jhep.2020.07.023

DO - 10.1016/j.jhep.2020.07.023

M3 - SCORING: Review article

C2 - 32707224

VL - 73

SP - 1496

EP - 1506

JO - J HEPATOL

JF - J HEPATOL

SN - 0168-8278

IS - 6

ER -